Targeting Oncogenic Driver Mutations in Lung Cancer

This Element summarises key oncogenic drivers, novel treatments and diagnostic strategies.

Matthew Lee (Author), Fawzi Abu Rous (Author), Alain Borczuk (Author), Stephen Liu (Author), Shirish Gadgeel (Author), Balazs Halmos (Author)

9781009336130, Cambridge University Press

Paperback / softback, published 2 February 2023

75 pages
22.7 x 15.2 x 0.7 cm, 0.16 kg

The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant oncogenic drivers other than EGFR, their management and current advancements in treatment. It also examines the different challenges in resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver and the future direction of NSCLC management.

1. Introduction
2. ALK gene rearrangements
3. ROSI gene rearrangements
4. RET gene rearrangements
5. MET alterations
6. KRAS point mutations
7. B-RAF point mutations
8. NTRK1/2/3 gene fusions
9. ERBB2 (HER2) mutations
10. Diagnostic strategies
References.

Subject Areas: Respiratory medicine [MJL], Oncology [MJCL], Medical diagnosis [MJA]